Strictly follow the recommended dosage unless directed otherwise by the physician.
Recommended Weekly Dose: One 35-mg tab orally at least 30 min before the 1st food or drink (other than water) of the day. The tablet should be taken on the same day each week.
Recommended Monthly Dose: One 150-mg tab orally at least 30 min before the 1st food or drink (other than water) of the day. The tablet should be taken on the same day each month.
Food and drinks may interfere with the absorption of Actonel. Therefore, it is very important not to take it with food, other medicinal products or drinks (other than water).
The tablet must be swallowed whole and not sucked or chewed. To aid delivery of the tablet to the stomach, Actonel is to be taken while in an upright position with a glass of plain water (180-240 mL). Patients should not lie down for 30 min after taking the tablet.
If the patient missed a dose, 1 tab should be taken on the day the tablet is remembered. Continue to take the tablet on the next day. Patients should then return to taking one 35-mg tab once a week on the day the tablet is normally taken. Do not take 2 tabs in 1 day instead of the tablet missed.
If the patient missed to take 150 mg tab and the next monthly dose is >7 days ahead, just take 1 tab the next morning. For the next monthly dose, take 1 tab as originally scheduled. If the patient missed to take 150 mg tab and the next monthly dose is within 7 days, do not take it. Return to taking 1 tab once a month, as originally scheduled on chosen day.
It is important that the diet includes products containing calcium and vitamin D (eg, dairy products). Supplemental calcium and vitamin D should be considered if the dietary intake is inadequate.
Elderly: No dosage adjustment is necessary since bioavailability, distribution and elimination were similar in elderly (>60 years) compared to younger subjects.
This has also been shown in the very elderly and postmenopausal population ≥75 years.
Renal Impairment: No dosage adjustment is required for those patients with mild to moderate renal impairment. The use of risedronate sodium is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min) (see Pharmacokinetics under Actions and Contraindications).